Entera Bio (NASDAQ:ENTX) Director Acquires $12,300.00 in Stock

Entera Bio Ltd. (NASDAQ:ENTX) Director Sean Ellis bought 10,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were bought at an average cost of $1.23 per share, with a total value of $12,300.00. Following the completion of the transaction, the director owned 188,098 shares in the company, valued at $231,360.54. The trade was a 5.61% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Sean Ellis also recently made the following trade(s):

• On Monday, February 9th, Sean Ellis purchased 18,000 shares of Entera Bio stock. The stock was bought at an average price of $1.24 per share, for a total transaction of $22,320.00.

Entera Bio Trading Down 6.7%

Shares of ENTX stock opened at $1.39 on Thursday. Entera Bio Ltd. has a 1-year low of $1.00 and a 1-year high of $3.22. The stock has a market cap of $63.75 million, a price-to-earnings ratio of -5.56 and a beta of 1.83. The stock has a 50-day moving average of $1.48 and a 200-day moving average of $1.96.

Hedge Funds Weigh In On Entera Bio

A number of institutional investors and hedge funds have recently modified their holdings of the business. Superstring Capital Management LP acquired a new stake in shares of Entera Bio during the 4th quarter worth approximately $33,000. Citadel Advisors LLC lifted its position in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after acquiring an additional 28,322 shares during the period. HighTower Advisors LLC boosted its stake in Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after acquiring an additional 25,000 shares in the last quarter. Jane Street Group LLC grew its holdings in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after purchasing an additional 19,601 shares in the last quarter. 14.11% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on ENTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research report on Monday, February 9th. Finally, Wall Street Zen raised shares of Entera Bio to a “sell” rating in a research note on Saturday, December 27th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $10.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.